Incyte (INCY) to Release Earnings on Tuesday

Incyte (NASDAQ:INCY - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Tuesday, July 29th. Analysts expect the company to announce earnings of $1.38 per share and revenue of $1.15 billion for the quarter.

Incyte (NASDAQ:INCY - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, beating analysts' consensus estimates of $1.01 by $0.15. The business had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $996.17 million. Incyte had a net margin of 0.48% and a return on equity of 2.77%. The firm's revenue was up 19.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.64 earnings per share. On average, analysts expect Incyte to post $5 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Incyte Price Performance

Shares of INCY traded down $0.06 during mid-day trading on Friday, reaching $70.43. The stock had a trading volume of 278,913 shares, compared to its average volume of 1,854,604. The firm has a market cap of $13.63 billion, a price-to-earnings ratio of 220.09, a PEG ratio of 0.60 and a beta of 0.68. Incyte has a 12 month low of $53.56 and a 12 month high of $83.95. The business has a fifty day moving average of $67.75 and a 200 day moving average of $66.63. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.00 and a current ratio of 2.04.

Analyst Ratings Changes

A number of equities analysts have weighed in on INCY shares. UBS Group reiterated a "neutral" rating and issued a $61.00 price target on shares of Incyte in a research report on Tuesday, June 3rd. Stifel Nicolaus upgraded shares of Incyte from a "hold" rating to a "buy" rating and upped their price target for the stock from $75.00 to $107.00 in a research report on Monday, June 16th. Citigroup reiterated a "buy" rating on shares of Incyte in a research report on Tuesday, June 3rd. Truist Financial upped their price target on shares of Incyte from $72.00 to $73.00 and gave the stock a "hold" rating in a research report on Tuesday, May 27th. Finally, Wells Fargo & Company upped their price target on shares of Incyte from $58.00 to $59.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $74.47.

Insider Buying and Selling at Incyte

In other Incyte news, EVP Barry P. Flannelly sold 10,903 shares of the stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $68.15, for a total transaction of $743,039.45. Following the completion of the transaction, the executive vice president owned 39,744 shares in the company, valued at $2,708,553.60. This trade represents a 21.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Steven H. Stein sold 14,952 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $68.47, for a total transaction of $1,023,763.44. Following the transaction, the executive vice president owned 97,466 shares of the company's stock, valued at $6,673,497.02. This trade represents a 13.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,098 shares of company stock worth $3,836,196 over the last three months. 17.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Incyte

Institutional investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. lifted its holdings in shares of Incyte by 350.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company's stock worth $46,000 after acquiring an additional 588 shares during the last quarter. Focus Partners Wealth lifted its holdings in shares of Incyte by 74.1% in the 1st quarter. Focus Partners Wealth now owns 21,024 shares of the biopharmaceutical company's stock worth $1,273,000 after acquiring an additional 8,951 shares during the last quarter. United Services Automobile Association bought a new stake in shares of Incyte in the 1st quarter worth about $219,000. Goldman Sachs Group Inc. lifted its holdings in shares of Incyte by 6.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 814,559 shares of the biopharmaceutical company's stock worth $49,322,000 after acquiring an additional 48,751 shares during the last quarter. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Incyte by 15.1% in the 1st quarter. Jones Financial Companies Lllp now owns 4,944 shares of the biopharmaceutical company's stock worth $299,000 after acquiring an additional 648 shares during the last quarter. Institutional investors own 96.97% of the company's stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.